Login to Your Account

Clinic Roundup

Wednesday, May 23, 2012
• Celtic Pharmaceutical Holdings LP, of New York, said it completed a Phase I/II study of Xerecept (corticorelin acetate) in pediatric patients who are dependent on the steroid Decadron (dexamethasone) to treat peritumoral brain edema associated with cerebral tumors. Initial indications from the 15-patient study indicated that Xerecept can reduce or eliminate the need for Decadron use and provide significant quality of life improvements.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription